Clinical trials: Tace
Intrahepatic Cholangiocarcinoma
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT06643208
- Testing
- TACE-HAIC, Envafolimab and Lenvatinib
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Fujian Provincial Hospital
Heptocellular Cancer, Biliary Tract Neoplasms
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Background: Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer.
- Conditions
- Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT01853618
- Testing
- Tremelimumab, RFA, TACE
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)
The objective of this study is to evaluate the efficacy and safety of TACE combined with Sintilimab plus bevacizumab biosimilar in patients with advanced hepatocellular carcinoma as first-line therapy.
- Trial name
- NCT04954794
- Testing
- Sintilimab, TACE
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis
The purpose of this study is to investigate safety and potential therapeutic benefits for patients with hepatocellular carcinoma by transcatheter chemoembolization with the recombinant endostatin (commercially available in…
- Trial name
- TACE HCC (NCT00518557)
- Testing
- Transcatheter Arterial Chemoembolization
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Southeast University, China
Hepatocellular Carcinoma
Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers
The purpose of this study is to id transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular targeted therapies in patients with hepatocellular carcinoma (HCC) .
- Trial name
- CHANCEsub (NCT05278195)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhongda Hospital
Unresectable Hepatocellular Carcinoma
DEB-TACE+HAIC vs. HAIC for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) plus hepatic artery infusion chemotherapy (HAIC) compared with HAIC alone for unresectable large…
- Trial name
- NCT05263219
- Testing
- dTACE-HAIC, HAIC, dTACE-HAIC protocol
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC
TACE is considered the standard treatment for unresectable HCC on the basis of the fact that there are no alternative to curative procedures.But the optimal combined regimen is still unclear.
- Trial name
- NCT01229839
- Testing
- Embolization, Infusion of anticancer agent, Infusion of mixture of anticancer agent and lipiodol
- Where
- China
- Volunteers
- 668 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Unresectable
Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma
Songyou Granule is a mixture of 6 herbs. Vitro and vivo studies showed that Songyou Granule can inhibit HCC cells grow, and HCC metastasis.
- Trial name
- NCT00805896
- Testing
- Songyou
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Fudan University
Carcinoma, Hepatocellular
CT Imaging for Guiding PA-TACE for HCC
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of…
- Trial name
- NCT06156748
- Testing
- postoperative adjuvant transarterial chemoembolization
- Where
- China
- Volunteers
- 1,770 people
- Sponsor
- Zhujiang Hospital
Antibiotic Prophylaxis
Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma
This study aims to determine the effectiveness of prophylactic antibiotic use for TACE and occurrence of postoperative liver abscess. There would be two comparison groups.
- Trial name
- NCT05654896
- Testing
- Ceftriaxone Sodium
- Where
- Pakistan
- Volunteers
- 158 people
- Sponsor
- Nadeem Iqbal
Advanced Hepatocellular Carcinoma
TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
This trial is is an open label, multicenter, randomized controlled phase 3 clinical trial. The purpose is to compare the efficacy and safety of lenvatinib plus TACE with lenvatinib alone for advanced HCC patients.
- Trial name
- TACE (NCT03905967)
- Testing
- TACE, Lenvatinib
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Sun Yat-sen University
TACE, HCC - Hepatocellular Carcinoma
Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)
Liver abscess is a rare but serious complication of hepatocellular carcinoma after TACE, with an incidence of less than 1% reported in previous literature.
- Conditions
- TACE, HCC - Hepatocellular Carcinoma, Liver Abscess
- Trial name
- NCT06483594
- Volunteers
- 400 people
- Sponsor
- Shengjing Hospital
HCC
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
Major objectives To evaluate the efficacy of lparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/ CTLA-4 Combined Antibody) in combination with TACE and lenvatinib as second-line therapy in patients with unresectable…
- Trial name
- NCT07099274
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization
The application of transarterial chemoembolisation (TACE) with drug-eluting beads in patients with hepatocellular carcinoma and its response to the treatment will be observed.
- Trial name
- NCT04780789
- Testing
- Transarterial Chemoembolization
- Volunteers
- 61 people
- Sponsor
- Brno University Hospital
Transarterial Embolism, Transarterial Chemoembolization
qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver
The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures.
- Conditions
- Transarterial Embolism, Transarterial Chemoembolization, Radioembolization
- Trial name
- NCT06971991
- Testing
- qDSA Blood Flow Measurement
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
This study is an open-label, randomized controlled, multicenter, phase III clinical trial
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE
- Trial name
- NCT07186621
- Testing
- Sintilimab, radiotherapy, TACE
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Transcatheter arterial chemoembolization (TACE) had been proved to improve the survivals for middle stage hepatocellular carcinoma (HCC), but for advanced stage HCC its' efficacy had not been proved.
- Trial name
- TACEHCC (NCT00646100)
- Testing
- transcatheter arterial chemoembolization
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Sun Yat-sen University
Recurrent Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)
To compare the efficacy of Transarterial Chemoembolization (TACE) to CyberKnife stereotactic body radiotherapy in the treatment of patients with locally recurrent hepatocellular carcinoma (HCC) after TACE.
- Trial name
- NCT01318200
- Testing
- Transarterial Chemoembolization, CyberKnife SBRT
- Where
- United States
- Sponsor
- Accuray Incorporated
Hepatocellular Carcinoma
The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a major tumor type worldwide, especially in China as the sequence of hepatitis B and liver cirrhosis. Activation of the coagulation system occurs commonly in patients with malignancy.
- Trial name
- NCT00827554
- Testing
- LMWH, TACE
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Carcinoma, Hepatocellular
Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Patients with liver tumor burden that exceeds Milan criteria are considered to receive one of the following locoregional treatments: transarterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol…
- Trial name
- NCT00857805
- Testing
- Transarterial Chemoembolization, Proton Beam Radiotherapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Loma Linda University